Welcome to our dedicated page for PERRIGO Co plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.
The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.
T. Rowe Price Associates, Inc. reports beneficial ownership of 8,700,421 shares of Perrigo Company plc common stock, representing 6.3% of the class as of June 30, 2026. It has sole voting power over 8,666,232 shares and sole dispositive power over 8,700,421 shares, with no shared voting or dispositive power.
The firm states that this report should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
Perrigo Company plc reported second‑quarter 2026 continuing‑operations net sales of $1,022.8 million, down 3.2% year over year, as category softness and lower retail inventories weighed on Core Self Care and Specialty Care. Reported diluted EPS was $0.63 versus $0.00, aided by the gain on the Dermacosmetics divestiture.
All In adjusted diluted EPS was $0.50, down from $0.57, with adjusted gross margin contracting to 35.6% and adjusted operating margin to 12.2%. Core net sales were $907 million, down 3.1%, while Infant Formula net sales rose 23.1% to $100.9 million with improved profitability.
The company generated $83 million of net cash from operating activities in the quarter ended June 27, 2026, held $400 million of cash and cash equivalents and had total debt of $3.3 billion. Approximately $359 million of Dermacosmetics proceeds were applied to debt reduction, and management reaffirmed 2026 adjusted EPS guidance of $2.00–$2.30 All In and $2.25–$2.55 Core.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 20,988,733 shares of Perrigo Company plc common stock. This represents 15.2% of the class as of the reported date.
BlackRock reports sole voting power over 20,758,891 shares and sole dispositive power over 20,988,733 shares, with no shared voting or dispositive power. The filing notes that certain business units of BlackRock are aggregated for this report, while others are disaggregated under SEC Release No. 34-39538. One such person, iShares Core S&P Small-Cap ETF, is stated to have an interest in more than five percent of Perrigo’s outstanding common stock.
Manzone Albert reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc granted its interim President and CEO, Albert Manzone, 235,627 Restricted Stock Units on July 8, 2026. Each RSU represents a contingent right to receive one ordinary share and will vest upon the earlier of July 8, 2027, the hiring of a permanent CEO, or termination of employment in connection with a change of control under Perrigo's 2026 Long-Term Incentive Plan. Following this award, Manzone directly holds 16,353 ordinary shares.
Amin Ahmed Salman reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc director Ahmed Salman Amin reported an equity compensation award. On July 8, 2026, he received 14,964 Restricted Stock Units, each representing a contingent right to one ordinary share, vesting on July 8, 2027. Following the grant, he holds 14,964 RSUs directly and no non-derivative shares.
Gajial Muhammad Omer reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc director Muhammad Omer Gajial reported a grant of 14,964 Restricted Stock Units. Each unit represents a contingent right to receive one ordinary share, with the award vesting on July 8, 2027. Following this grant, he holds 14,964 RSUs directly.
Perrigo Co plc director Muhammad Omer Gajial filed an initial beneficial ownership report stating that he does not beneficially own any Perrigo securities. The report shows a total of 0.0000 shares held directly following the holding entry dated June 30, 2026.
PERRIGO Co plc director Ahmed Salman Amin filed an initial ownership report stating that he currently has no securities beneficially owned in the company. The filing shows direct ownership of 0 shares following the reported holdings entry.
Bezerra Eduardo Guarita reported acquisition or exercise transactions in this Form 4 filing.
PERRIGO Co plc executive Eduardo Guarita Bezerra, EVP & Chief Financial Officer, reported an equity award and updated holdings. He received a grant of 141,376 Restricted Stock Units, each representing a contingent right to receive one ordinary share, with vesting on July 8, 2027. Following the reporting date, he holds 84,700 ordinary shares directly.